Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 20000 participants.

Also called NCT05874635

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 20,000 participants (planned count) (from the registry)
Sponsor
Signos Inc (from the registry)
Registry
  • NCT NCT05874635
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05874635. Allocation not applicable; no masking; primary purpose treatment. Start 2023-05-11 (actual); primary completion 2028-05-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)
Condition
Weight Loss
Condition
Diabetes Mellitus, Type 2
Condition
Central Obesity
Condition
Glucose Intolerance
Condition
Metabolic Glucose Disorders
Intervention (Device)
Continuous Glucose Monitor Device
Lead sponsor
Signos Inc (class: industry)

Record details

Record id
cardio:ct-nct05874635
Content hash
a47909d70f746e6fd37a819a1cef6835a705c17fba5947d7089f98cf0dbe4d06